HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $6 price target.
April 09, 2024 | 10:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Elevation Oncology with a $6 price target.
The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Elevation Oncology. This endorsement may lead to increased investor confidence in ELEV, potentially driving up its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100